UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000038465
Receipt No. R000043802
Scientific Title Evaluation of cognitive function maintenance or improvement effect of functional food in healthy adults -Placebo-controlled randomized, double-blind study-
Date of disclosure of the study information 2021/03/01
Last modified on 2021/03/11 (Ver. 2)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Evaluation of cognitive function maintenance or improvement effect of functional food in healthy adults
-Placebo-controlled randomized, double-blind study-
Acronym Evaluation of cognitive function maintenance or improvement effect of functional food in healthy adults
Scientific Title Evaluation of cognitive function maintenance or improvement effect of functional food in healthy adults
-Placebo-controlled randomized, double-blind study-
Scientific Title:Acronym Evaluation of cognitive function maintenance or improvement effect of functional food in healthy adults
Region
Japan

Condition
Condition Healthy elderly adults with poor cognitive performance, MCI
Classification by specialty
Neurology Geriatrics Psychiatry
Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 We examine the maintenance or improvement effect of cognitive function and the safety when the elderly subjects take functional food for 12 weeks.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Cognitrax
Key secondary outcomes Various cognitive function tests and questionnaires, blood and urine tests

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Prevention
Type of intervention
Food
Interventions/Control_1 Ingestion of functional food for 12 weeks
Interventions/Control_2 Ingestion of placebo for 12 weeks
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
40 years-old <=
Age-upper limit
80 years-old >
Gender Male and Female
Key inclusion criteria 1. Japanese men and women aged greater than or equal to 40 years, less than 80 years at the time of obtaining informed consent.
2. Subjects with MMSE score of 24 to 29 at screening.
3. Subjects who have subjective forgetfulness or have been pointed out forgetfulness by others.
4. Subjects who got adequate explanation about the purpose and details of the examination, have the capacity to consent, voluntarily participate in understanding, and agree to participate in the examination in writing.
Key exclusion criteria 1. Subjects who judged by a doctor as dementia.
2. Subjects who have taken or had taken drugs of dementia.
3. Subjects who regularly take drugs that may affect cognitive functions.
4. Subjects who have current medical history or past medical history of mental disorders (including depressive symptoms) or cerebrovascular diseases.
5. Subjects who regularly use supplements or health foods that may affect cognitive functions.
6. Subjects who judged inappropriate as subjects as a result of clinical examination of screening.
7. Subjects with gerontological depression scale (GDS-S-J) scores of 6 or more.
8. Subjects who have history of alcohol dependence or current medical history.
9. Subjects who consume a large amount of alcohol routinely.
10. Subjects who have serious illness or medical history such as diabetes, liver disease, kidney disease, heart disease.
11. Subjects who have medical history or history of food allergies or current medical history.
12. Subjects who have color vision disorder and can not easily hear people's talk at short distance.
13. Subjects who have problems with the functions of both hands due to injury, surgery, etc.
14. Subjects who are planning to participate and/or had participated in other clinical studies within the last one month prior to the current study.
15. Subjects who are judged as unsuitable for the current study by the investigator for other reasons.
Target sample size 90

Research contact person
Name of lead principal investigator
1st name Yoshitaka
Middle name
Last name Iwama
Organization Nihonbashi Cardiology Clinic
Division name Director
Zip code 103-0001
Address Kyodo Bldg. #201, 13 - 4 Nihonbashi Kodenmacho, Chuo-ku, Tokyo
TEL 03-5641-4133
Email yiwama@well-sleep.jp

Public contact
Name of contact person
1st name Yoshika
Middle name
Last name Komori
Organization KSO Corporation
Division name Sales department
Zip code 105-0023
Address Shibaura OMODAKA Bldg. 7F, 1-9-7 Shibaura, Minato-ku, Tokyo
TEL 03-3452-7733
Homepage URL
Email yoshi@kso.co.jp

Sponsor
Institute KSO Corporation
Institute
Department

Funding Source
Organization Yamada Bee Company, Inc.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Nihonbashi Cardiovascular Department Clinic Ethics Committee
Address Kyodo Bldg. #201, 13 - 4 Nihonbashi Kodenmacho, Chuo-ku, Tokyo
Tel 03-5641-4133
Email yiwama@well-sleep.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2021 Year 03 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2019 Year 10 Month 08 Day
Date of IRB
2019 Year 10 Month 11 Day
Anticipated trial start date
2019 Year 11 Month 08 Day
Last follow-up date
2020 Year 02 Month 22 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2019 Year 11 Month 01 Day
Last modified on
2021 Year 03 Month 11 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043802